The Prescription Drug and User Fee Act (PDUFA) IV will expire in September 2012. A new version of this legislation, PDUFA V, is expected in the coming months and may have implications for your regulatory strategy and development program. Join David Shoemaker, Ph.D. as he discusses the history of PDUFA and what may be included in the upcoming version.
Senior Vice President
- What Non-statisticians Need to Know about Statistics in Clinical Trials
- Using FDA’s Draft Guidance on Risk-Based Monitoring to Improve Clinical Data Quality
- Targeted Product Development: Personalized Medicine versus Orphan Product Development
- Stop the pain: Tips for increasing patient retention and decreasing missing data in analgesia clinical trials